These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 26346504)

  • 1. Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel.
    Moawad EY
    J Gastrointest Cancer; 2015 Dec; 46(4):380-9. PubMed ID: 26346504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
    Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
    Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
    Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
    Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide.
    Santo L; Hideshima T; Cirstea D; Bandi M; Nelson EA; Gorgun G; Rodig S; Vallet S; Pozzi S; Patel K; Unitt C; Squires M; Hu Y; Chauhan D; Mahindra A; Munshi NC; Anderson KC; Raje N
    Clin Cancer Res; 2011 May; 17(10):3259-71. PubMed ID: 21430070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AT9283, a potent inhibitor of the Aurora kinases and Jak2, has therapeutic potential in myeloproliferative disorders.
    Dawson MA; Curry JE; Barber K; Beer PA; Graham B; Lyons JF; Richardson CJ; Scott MA; Smyth T; Squires MS; Thompson NT; Green AR; Wallis NG
    Br J Haematol; 2010 Jul; 150(1):46-57. PubMed ID: 20507304
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal standard regimen and predicting response to docetaxel therapy.
    Moawad EY
    Mutat Res; 2014 Dec; 770():120-7. PubMed ID: 25771878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity.
    Howard S; Berdini V; Boulstridge JA; Carr MG; Cross DM; Curry J; Devine LA; Early TR; Fazal L; Gill AL; Heathcote M; Maman S; Matthews JE; McMenamin RL; Navarro EF; O'Brien MA; O'Reilly M; Rees DC; Reule M; Tisi D; Williams G; Vinković M; Wyatt PG
    J Med Chem; 2009 Jan; 52(2):379-88. PubMed ID: 19143567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis.
    Foran J; Ravandi F; Wierda W; Garcia-Manero G; Verstovsek S; Kadia T; Burger J; Yule M; Langford G; Lyons J; Ayrton J; Lock V; Borthakur G; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2014 Jun; 14(3):223-30. PubMed ID: 24355079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adaptation of the plasma inhibitory activity assay to detect Aurora, ABL and FLT3 kinase inhibition by AT9283 in pediatric leukemia.
    Podesta JE; Sugar R; Squires M; Linardopoulos S; Pearson AD; Moore AS
    Leuk Res; 2011 Sep; 35(9):1273-5. PubMed ID: 21665275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
    Arkenau HT; Plummer R; Molife LR; Olmos D; Yap TA; Squires M; Lewis S; Lock V; Yule M; Lyons J; Calvert H; Judson I
    Ann Oncol; 2012 May; 23(5):1307-1313. PubMed ID: 22015452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repurposed AT9283 triggers anti-tumoral effects by targeting MKK3 oncogenic functions in Colorectal Cancer.
    Piastra V; Ganci F; Sacconi A; Pranteda A; Allegretti M; Bernardini R; Serra M; Lupo B; Dell'Aquila E; Ferretti G; Pescarmona E; Bartolazzi A; Blandino G; Trusolino L; Bossi G
    J Exp Clin Cancer Res; 2024 Aug; 43(1):234. PubMed ID: 39164711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.
    Hay AE; Murugesan A; DiPasquale AM; Kouroukis T; Sandhu I; Kukreti V; Bahlis NJ; Lategan J; Reece DE; Lyons JF; Sederias J; Xu H; Powers J; Seymour LK; Reiman T
    Leuk Lymphoma; 2016; 57(6):1463-6. PubMed ID: 26376958
    [No Abstract]   [Full Text] [Related]  

  • 14. Occurrence and modulation of therapeutic targets of Aurora kinase inhibition in pediatric acute leukemia cells.
    Jayanthan A; Cooper TM; Hoeksema KA; Lotfi S; Woldum E; Lewis VA; Narendran A
    Leuk Lymphoma; 2013 Jul; 54(7):1505-16. PubMed ID: 23176524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
    Amino N; Ideyama Y; Yamano M; Kuromitsu S; Tajinda K; Samizu K; Hisamichi H; Matsuhisa A; Shirasuna K; Kudoh M; Shibasaki M
    Clin Cancer Res; 2006 Mar; 12(5):1630-8. PubMed ID: 16533791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis.
    Naumova E; Ubezio P; Garofalo A; Borsotti P; Cassis L; Riccardi E; Scanziani E; Eccles SA; Bani MR; Giavazzi R
    Clin Cancer Res; 2006 Mar; 12(6):1839-49. PubMed ID: 16551869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283.
    Petersen W; Liu J; Yuan L; Zhang H; Schneiderjan M; Cho YJ; MacDonald TJ
    Cancer Lett; 2014 Nov; 354(1):68-76. PubMed ID: 25107642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer.
    Zeng WG; Li JJ; Hu P; Lei L; Wang JN; Liu RB
    Oncol Rep; 2013 Jun; 29(6):2355-61. PubMed ID: 23525624
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p38alpha-selective MAP kinase inhibitor reduces tumor growth in mouse xenograft models of multiple myeloma.
    Medicherla S; Reddy M; Ying J; Navas TA; Li L; Nguyen AN; Kerr I; Hanjarappa N; Protter AA; Higgins LS
    Anticancer Res; 2008; 28(6A):3827-33. PubMed ID: 19189670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of 12-O-tetradecanoylphorbol-13-acetate (TPA) in combination with paclitaxel (Taxol) on prostate Cancer LNCaP cells cultured in vitro or grown as xenograft tumors in immunodeficient mice.
    Zheng X; Chang RL; Cui XX; Avila GE; Hebbar V; Garzotto M; Shih WJ; Lin Y; Lu SE; Rabson AB; Kong AN; Conney AH
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3444-51. PubMed ID: 16740769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.